ripekg:author/RIPEAU390929084ABE0B3ELars Klareskog |
rdf:type |
node1 |
ripekg:author/RIPEAU390929084ABE0B3ELars Klareskog |
rdf:type |
rdfs:Resource |
ripekg:author/RIPEAU390929084ABE0B3ELars Klareskog |
rdf:type |
owl:Thing |
ripekg:author/RIPEAU390929084ABE0B3ELars Klareskog |
rdf:type |
prov:Person |
ripekg:author/RIPEAU390929084ABE0B3ELars Klareskog |
rdf:type |
foaf:Person |
ripekg:author/RIPEAU390929084ABE0B3ELars Klareskog |
rdf:type |
ripe:AuthorAuthor |
ripekg:author/RIPEAU390929084ABE0B3ELars Klareskog |
owl:sameAs |
https://semopenalex.org/author/A5071491614 |
ripekg:author/RIPEAU390929084ABE0B3ELars Klareskog |
http://www.w3.org/ns/org#memberOf |
ripekg:organization/RIPEOC335D2A7F4D3B7D1Rheumatology Unit |
ripekg:author/RIPEAU390929084ABE0B3ELars Klareskog |
foaf:familyName |
Klareskog |
ripekg:author/RIPEAU390929084ABE0B3ELars Klareskog |
foaf:givenName |
Lars |
ripekg:author/RIPEAU390929084ABE0B3ELars Klareskog |
foaf:name |
Lars Klareskog |
ripekg:retraction-notice/19710Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition |
ripe:concerns |
ripekg:author/RIPEAU390929084ABE0B3ELars Klareskog |
ripekg:work/10.1136%2Fannrheumdis-2014-205698Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial |
dcterms:creator |
ripekg:author/RIPEAU390929084ABE0B3ELars Klareskog |